TAK dividend history

Year-to-Date Revenue Declined by 2.8% at Constant Exchange Rate (CER), 3.3% at Actual Exchange Rates (AER); Impact of VYVANSE® Generics is Tapering Off Core Operating Profit Declined by 3.4% at both CER and AER Year to Date Reported Operating Profit Increased by 1.2% at AER Year to Date, Lower Restructuring Expenses More Than Offset Impairment   Takeda ((4502, NYSE:TAK) today announced earnings results for the third quarter of fiscal year 2025 (nine months ended December 31, 2025). The gap between incremental Growth & Launch Products revenue and VYVANSE erosion is narrowing, and operational efficiencies drove year-on-year reductions in operating expenses, including R&D. The comp

First Half Revenue Declined 3.9% at Constant Exchange Rate (CER), -6.9% at Actual Exchange Rates (AER), Impacted by Generic Erosion of VYVANSE® and FX Headwind Core Operating Profit Declined 8.8% at CER in the First Half, Reflecting Revenue Performance and Product Mix; Impact Partially Offset by Operational Efficiencies First Half Reported Operating Profit (-27.7% at AER) Impacted by Impairment Losses Incurred in Q2   Takeda ((4502, NYSE:TAK) today announced earnings results for the first half of fiscal year 2025 (six months ended Sep 30, 2025) and updated its full-year outlook. Takeda chief executive officer, Christophe Weber, commented: "Takeda's fiscal year 2025 first half

Revenue Decline of 3.7% at Constant Exchange Rate (CER); 8.4% Decline at Actual Exchange Rates (AER) as VYVANSE® Generic Erosion Impacts Revenue in Line With Company Expectations Core Operating Profit Decline of 11.9% at CER, Primarily Reflecting Generic Erosion Reported Operating Profit Increase of 11.0% at AER, Reflecting Lower YoY Impairment and Restructuring Expenses Positive Results from Two Pivotal Phase 3 Studies of Oveporexton in Narcolepsy Type 1 Reinforce Continued Momentum in Late-Stage Pipeline No Change to Full-Year Outlook Announced in May Takeda ((4502, NYSE:TAK) today announced earnings results for the first quarter of fiscal year 2025 (three months ended Jun

Core Revenue Growth of 7.4% at Actual Exchange Rates (AER), + 2.8% at Constant Exchange Rate (CER) in FY2024 Core Operating Profit Growth of 4.9% at CER with Efficiency Program Driving Cost Savings Up to Six New Molecular Entities in Phase 3 Development in FY2025 with Three Phase 3 Data Readouts Recently Completed or Anticipated FY2025 Outlook for Broadly Flat Revenue and Core Profit Reflecting Product Momentum and Increasing Investment in New Launch Preparation Proposed Dividend Increase from JPY 196 to JPY 200 Takeda ((4502, NYSE:TAK) today announced financial results for fiscal year 2024 (period ended March 31, 2025) with continued strong momentum in Growth & Launch Products o

Revenue Growth of +9.8% at Actual Exchange Rates (AER); +4.5% at Constant Exchange Rate (CER) Driven by Strong Momentum of Growth & Launch Products (+14.6% at CER) Core Operating Profit Increase of +10.1% at CER; Core OP Margin Climbs to 28.5% Reported Operating Profit +86.3% at AER Reflects Lower Impairment of Intangible Assets Compared to FY2023 Raises Adjusted Free Cash Flow Forecast Range by JPY 150.0 billion to JPY550.0 - JPY650.0 billion Announces Share Buyback of up to JPY 100.0 billion Takeda ((4502, NYSE:TAK) today announced earnings results for the third quarter of fiscal year 2024 (nine months ended December 31, 2024) showing continued advancement of its Growth &

Revenue Growth of +13.4% at Actual Exchange Rates (AER); +5.0% at Constant Exchange Rate (CER) Driven by Continued Advancement of Growth & Launch Products (+18.7% at CER) Core Operating Profit Increase of +12.9% at CER; Core Operating Profit Margin of 30.2% Double-Digit Revenue Growth of ENTYVIO® at CER Driven by Launch of ENTYVIO® Pen in the U.S. Geographical Expansion with Approvals of ADZYNMA® in EU and FRUZAQLA® in Japan Late-Stage Pipeline Advances with the Start of Phase 3 Trial of TAK-861 in Narcolepsy Type 1 Company will Hold R&D Day for Investors and Media on December 12 (Eastern) / 13 (Japan) Takeda ((4502, NYSE:TAK) today announced earnings results for the first half

Revenue Growth of 14.1% at Actual Exchange Rates (AER); +2.1% at Constant Exchange Rate (CER) Driven by Acceleration of Growth & Launch Products (+17.8% at CER) Core Operating Profit Increase of 4.5% at CER Reflecting Phasing of R&D Investment and Other OPEX Reduction; Core Operating Profit Margin of 31.6% for the Quarter No Change to Full Year Forecast or Management Guidance Geographic Expansion with Approvals of LIVTENCITY® in Japan and FRUZAQLA® in EU Late-Stage Pipeline Advances with Positive Phase 2b Data Presented for TAK-861 in Narcolepsy Type 1 and Mezagitamab for Immune Thrombocytopenia (ITP) Takeda ((4502, NYSE:TAK) today announced earnings results for the first qu

Revenue Growth of +5.9% at Actual Exchange Rates (AER); +1.5% at Constant Exchange Rate (CER) Driven by Growth & Launch Products Core Operating Profit Change of -13.3% at CER Reflecting Generic Impact and Investment in R&D and Data, Digital & Technology Three New Molecular Entity (NME) Approvals from U.S. FDA in FY2023 Up to Six NMEs with Significant Revenue Potential in Phase 3 Development in FY2024 Committed to 100-250 Basis Points Core Operating Profit Margin Improvement Each Year from FY2025 Towards Low-to-Mid 30s% Target Takeda (TYO:4502, NYSE:TAK) today announced financial results for fiscal year 2023 (period ended March 31, 2024), delivering its Management Guidance fo

Two New U.S. FDA Approvals in FY2023 Q3: FRUZAQLA for Adults With Previously Treated Metastatic Colorectal Cancer and ADZYNMA for Ultra-Rare Blood Clotting Disorder cTTP Strong Commercial Execution Maximizing Value of Existing Portfolio: ENTYVIO® Pen Launched in U.S. for Ulcerative Colitis; U.S. FDA Approval Decision on Crohn's Disease Filing Expected in early FY2024 QDENGA ® Dengue Vaccine Now Launched in 21 Countries LIVTENCITY ® Approved in China for Refractory Post-Transplant CMV Revenue Growth of +4.6% at Actual Exchange Rate (AER); Flat at Constant Exchange Rate (CER) Core Operating Profit Change of -12.7% at CER, Reflecting Generic Impact, Lower Coronavirus Vacci

Revenue Growth of +6.4% at Actual Exchange Rate (AER); +1.4% Growth at Constant Exchange Rate (CER), Driven by Growth & Launch Products (+13% at CER) Core Operating Profit Year-on-Year Change of -9.5% at CER Reflecting Generic Impact, Lower Demand for Coronavirus Vaccines and Increased Investment in R&D and Data & Technology Reported Operating Profit and Net Profit Impacted by Non-Cash Impairment of Intangible Assets Booked in Q2 Raising Full Year Revenue and Core EPS Forecasts to Reflect Updated FX and Tax Rate Assumptions; Lowering Full-Year Profit Forecasts on a Reported Basis Due to Non-Core Items Booked in Q2 No Change to Free Cash Flow Outlook or Management Guidance Ta

No Change to Full-Year Forecasts or Management Guidance Revenue Growth of +8.9% at Actual Exchange Rate (AER); +3.7% Growth at Constant Exchange Rate (CER), Driven by Growth & Launch Products (+16.2% at CER) Reported Operating Profit Growth of +12.0% at AER; Core Operating Profit Decline of -2.0% at CER Reflecting Generic Impact, Lower Demand for Coronavirus Vaccines and Increased Investment in R&D and Data & Technology Core Operating Profit Margin of 30.8% Anticipated Pipeline Advances with 8 Key Regulatory Decisions Expected by End of FY2023, Furthering Commitment to Delivering Life-transforming Medicines to Patients Takeda (TYO:4502, NYSE:TAK) today announced strong finan

Full Year Reported Revenue Growth of +12.8%; Core Revenue Growth of +3.5% at Constant Exchange Rate Driven by Growth & Launch Products; Reported EPS Growth of +38.8% Achieved Core Operating Profit of 1,188.4 Billion Yen – Exceeding 1 Trillion Yen for the First Time in the Company's History FY2023 Core Operating Profit Expected to Remain >1 Trillion Yen Despite Impact of Loss of Exclusivity and Lower Expectations for Coronavirus Vaccines Planned Dividend Increase to 188 Yen per Share in FY2023 Takeda ((4502, NYSE:TAK) today announced strong financial results for fiscal year 2022 (period ended March 31, 2023), delivering or exceeding management guidance, driven by the performance

Announced Agreement With Nimbus Therapeutics in December to Acquire a Potential Best-in-Class TYK2 Inhibitor, and with HUTCHMED in January to In-license Highly Selective, Oral Tyrosine Kinase Inhibitor Continued Momentum With Q3 Year-to-Date Reported Revenue Growth of +13.9% and Core Revenue Growth of +4.5% at Constant Exchange Rate; Reported EPS Growth of +19.6% Approval for Dengue Vaccine, QDENGA® in EU; U.S. FDA Priority Review Granted Net Debt / Adjusted EBITDA Improves to 2.5x as of Q3 End Even After Full-year Dividend Payment Robust Cash Flow and Improved Debt Profile Enabling Investment for Growth While Maintaining Focus on Shareholder Returns Takeda (TYO:4502, NYSE:TAK) t

Strong Start to Fiscal Year with H1 Core Revenue Growth of +5.5% at Constant Exchange Rate (CER); Reported Revenue Growth +10.1% Core Operating Profit Growth of +14.5% at CER; Core Operating Profit Margin of 31.7% Reported Operating Profit Growth Affected by One-time Gain Booked in FY2021 Q1 from Sale of Diabetes Portfolio in Japan and FX Impact Updating Peak Sales Outlook for ENTYVIO® to $7.5-9.0B Net Debt / Adjusted EBITDA Improved to 2.6x; Well-balanced Maturity Profile with 98% of Debt at Fixed Rates at Average 2% Interest Upgrading Full-Year Reported and Core Forecasts and Free Cash Flow Outlook, and Reconfirming Management Guidance Takeda (TYO:4502, NYSE:TAK) today announ

Q1 FY2022 Results Demonstrate a Strong Start to the Year with Core Revenue Growth at Constant Exchange Rate (CER) of +8.3% (Reported Revenue +2.4%) Growth and Launch Products Delivering Revenue Growth of +26% at CER Core Operating Profit Growth of +17% at CER, Core Operating Profit Margin 32.8% Reported Revenue and Operating Profit Growth Affected by One-time Gain Booked in Q1 of Prior Year from Sale of Diabetes Portfolio in Japan Continued Resilience in Challenging Macro Environment Takeda (TYO:4502, NYSE:TAK) today announced strong financial results for the first quarter of fiscal year 2022 (period ended June 30, 2022) and is on track to meet its full-year management guidance.

- Strong Performance Against FY2021 Management Guidance with Underlying Revenue Growth of +7.4% (Reported Revenue Growth +11.6%) and Strength Across Key Business Areas - Highest Total Number of Approvals for Takeda in a Fiscal Year Across Japan (4 NMEs), China (3 NMEs), the U.S. (2 NMEs), and Europe (1 NME) - Robust Free Cash Flow of JPY 943.7 Billion ($7.8B); Net Debt/Adjusted EBITDA of 2.8x - FY2022 Outlook for Continued Topline and Core EPS Growth; Core Operating Profit Forecast to Reach JPY 1.1 Trillion and Reported Net Profit to Increase +26.9% Takeda ((4502, NYSE:TAK) today announced strong financial results for fiscal year 2021 (period ended March 31, 2022), driven by the perform

Delivered Q3 FY2021 Year-to-Date Growth in Reported Revenue of +11% Grew Q3 FY2021 Year-to-Date Reported Operating Profit to 462.5 Billion Yen ($4.0B) and Delivered Competitive Underlying Core Operating Profit Margin of 29.4% 14 Global Brands Represent 42% of Year-to-Date Core Revenue with +12% Underlying Growth and Further Growth Expected in Q4 FY2021 Takeda (TYO:4502, NYSE:TAK) today announced strong financial results for the third quarter of its fiscal year 2021 (period ended December 31, 2021) driven by robust topline growth of its 14 global brands. Based on the strong third-quarter results and business momentum, the company upgraded forecasts for full fiscal year revenue, report

(Pursuant to the provision of its Articles of Incorporation in accordance with Article 459, paragraph 1 of the Companies Act of Japan) Takeda Pharmaceutical Company Limited ((4502, NYSE:TAK) ("Takeda") announced that its Board of Directors resolved today to engage in the acquisition of its own shares pursuant to the provision of its Articles of Incorporation in accordance with Article 459, paragraph 1 of the Companies Act of Japan, as detailed below. "At our current share price, we see an opportunity to buy back our shares at a substantial discount to what we perceive is their underlying value," said Costa Saroukos, director and Chief Financial Officer of Takeda. "We expect that this shar

Delivered H1 Year-Over-Year Growth in Reported Revenue of +12.8% and Underlying Revenue of +6.8% 14 Global Brands Represent 42% of Total Core Revenue with +11.4% Underlying Growth in H1; Further Acceleration Expected through H2 Highly Innovative Pipeline Poised to Deliver Over the Short- and Long-term Confirmed Full Year Management Guidance, On Track for Underlying Core Operating Profit Margin Target of Approximately 30% Announces Share Buyback of Up to 100B Yen Takeda Pharmaceutical Company Limited (TYO:4502, NYSE:TAK) ("Takeda") today announced financial results for the first half of fiscal year 2021 (period ended September 30, 2021). Based on the strong first half results, the

Delivered FY2020 Management Guidance with Results Driven by +16% Underlying Revenue Growth of 14 Global Brands (e.g., ENTYVIO ® +26.2% YOY, TAKHZYRO® +30.0% YOY, Immunoglobulin + 15.7% YOY) Accelerated Cost Synergies and Achieved $2.3 Billion Target One Year Ahead of Plan Reported Net Profit Growth of Approximately +750% YOY, Reflecting Gains on Non-core Asset Sales and Lower Acquisition-related Expenses Robust Operating Cash Flow and Divestiture Proceeds Resulting in Free Cash Flow of JPY 1,237.8 Billion, Driving Deleveraging to Net Debt / Adjusted EBITDA of 3.2x FY2021 Anticipated to be an Inflection Year for Wave 1 Pipeline with Five to Six Wave 1 NMEs Submitted and Under Regul

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) today announced financial results for the third quarter of fiscal year 2020 (period ended December 31, 2020). TAKEDA CHIEF FINANCIAL OFFICER COSTA SAROUKOS commented: “Our third-quarter results demonstrate the resilience of our business model and the depth of our portfolio, with strong growth generated by our 14 global brands. As a values-based and R&D driven biopharmaceutical company, we remain focused on bringing life-transforming treatments to people with high unmet needs around the world. With the first of our seven potential filings in the next 12 months complete, we look f

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) provided an update on the progress of its continued transformation and growth today at the virtual 39th Annual J.P. Morgan Healthcare Conference. President and Chief Executive Officer, Christophe Weber, shared details on Takeda’s portfolio and pipeline strategy and financial outlook, including key programs expected to contribute to the company’s revenue growth over the next decade. “In 2020, Takeda demonstrated the resilience of our business model, the depth of our portfolio and the commitment of our employees as we continued to serve patients and communities glo